AKT1 and neoplasm: Of note, one of these studies [58] showed that despite pharmacodynamic evidence of target inhibition in surrogate tissues, there was no significant inhibition of AKT in the tumours of patients treated with tolerable doses of MK-2206, suggesting that the lack of clinical benefit could be partly due to suboptimal pharmacology.